Jump to content

Medication-related osteonecrosis of the jaw

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Doc James (talk | contribs) at 03:46, 6 October 2018 (simpified). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Medication-related osteonecrosis of the jaw
Other namesMON of the jaw, medication-related osteonecrosis of the jaw (MRONJ), medication-induced osteonecrosis of the jaw (MIONJ)
SpecialtyRheumatology, oral and maxillofacial surgery Edit this on Wikidata

Medication-related osteonecrosis of the jaw (MON, MRONJ) is progressive death of the jawbone in a person exposed to a medications known to increase the risk of disease, in the absence of a previous radiation treatment. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy.[1]

Particular medications can result in MRONJ, a serious but uncommon side effect in certain individuals. Such medications are frequently used to treat diseases that cause bone resorption such as osteoporosis, or to treat cancer. The main groups of drugs involved are anti-resorptive drugs, and anti-angiogenic drugs.

This condition was previously known as bisphosphonate-related osteonecrosis of the jaw because osteonecrosis of the jaws correlating with bisphosphate treatment was frequently encountered, with its first incident occurring in 2003.[2][3][4][5] Denosumab, another antiresorptive drug were also related to this condition. However, newer medications such as anti-angiogenic drugs has been established over the years which were reported to be related to osteonecrosis of the jaw as a side-effect too, hence this condition has been renamed as MRONJ.[4]

BON was been nicknamed "bis-phossy jaw"[6] based on its similarity with phossy jaw. There is no known prevention for bisphosphonate-associated osteonecrosis of the jaw.[7] Avoiding the use of bisphosphonates is not a viable preventive strategy on a general-population basis because the medications are beneficial in the treatment and prevention of osteoporosis (including prevention of bony fractures) and treatment of bone cancers.

It usually develops after dental treatments involving exposure of bone or trauma, or may arise spontaneously. Patients who develop MRONJ may experience prolonged healing, pain, swelling, infection, exposed bone, after dental procedures, though some patients may have no signs/symptoms.[8]

Frequency and incidence

The likelihood of this condition developing varies widely from less than 1/10,000 to 1/100, as many other factors need to be considered, such as the type, dose and frequency of intake of drug, how long it has been taken for, and why it has been taken.[9]

In patients taking drugs for cancer, the likelihood of MRONJ development varies from 0 - 12%. This again, varies with the type of cancer, although prostate cancer and multiple myeloma are reported to be at a higher risk.[8]

In patients taking drugs for osteoporosis, the likelihood of MRONJ development varies from 0 - 0.1%.[8]

Definition

This condition is defined as exposed bone or bone that can be probed through an intraoral or extraoral fistula, in the maxillofacial region that has persisted for more than eight weeks in patients with a history of treatment with anti-resorptive or anti-angiogenic drugs, and without a history of radiation therapy to the jaw or no obvious metastatic disease to the jaws.[10]

Osteonecrosis, or localized death of bone tissue, of the jaws is a rare potential complication in cancer patients receiving treatments including radiation, chemotherapy, or in patients with tumors or infectious embolic events. In 2003,[11][12] reports surfaced of the increased risk of osteonecrosis in patients receiving these therapies concomitant with intravenous bisphosphonate.[13] Matrix metalloproteinase 2 may be a candidate gene for bisphosphonate-associated osteonecrosis of the jaws, since it is the only gene known to be associated with both bone abnormalities and atrial fibrillation, another side effect of bisphosphonates.[14]

In response to the growing base of literature on this association, the United States Food and Drug Administration issued a broad drug class warning of this complication for all bisphosphonates in 2005.[15]

Signs and symptoms

Lesions and areas of necrotic bone may remain asymptomatic for weeks, months, or even years,[16] and most commonly become symptomatic with inflammation of surrounding tissues.[17] Clinical signs and symptoms associated with but not limited to BONJ include the following:

Pathogenesis

Although the methods of action are not yet completely understood, it is hypothesized that medication-associated osteonecrosis of the jaw is related to a defect in jaw bone healing and remodelling. The condition is predominantly confined within the maxillofacial region.

The inhibition of osteoclast differentiation and function, precipitated by drug therapy, leads to decreased bone resorption and remodelling.[22][23] Evidence also suggests bisphosphonates induce apoptosis of osteoclasts, resulting in resorption of bones.[24] Another suggested factor is the inhibition of angiogenesis due to bisphosphonates but its effect remains uncertain.[25][26][27] Several studies have proposed that bisphosphonates cause excessive reduction of bone turnover, resulting in a higher risk of bone necrosis when repair is needed.[28][29][30]

Light micrograph of an osteoclast displaying typical distinguishing characteristics: a large cell with multiple nuclei and a "foamy" cytosol.

Because bisphosphonates are preferentially deposited in bone with high turnover rates, it is possible that the levels of bisphosphonate within the jaw are selectively elevated. To date, there have been no reported cases of bisphosphonate-associated complications within bones outside the craniofacial skeleton.[15]

Diagnosis

A diagnosis of bisphosphonate-associated osteonecrosis of the jaw relies on three criteria:[7]

  1. the patient possesses an area of exposed bone in the jaw persisting for more than 8 weeks,
  2. the patient must present with no history of radiation therapy to the head and neck
  3. the patient must be taking or have taken bisphosphonate medication.

According to the updated 2009 BRONJ Position Paper published by the American Association of Oral and Maxillofacial Surgeons, both the potency of and the length of exposure to bisphosphonates are linked to the risk of developing bisphosphonate-associated osteonecrosis of the jaw.[31]

Cause

Cases of BRONJ have also been associated with the use of the following two intravenous and three oral bisphosphonates, respectively: Zometa (zoledronic acid) and Aredia (pamidronate) and Fosamax (alendronate), Actonel (risedronate), and Boniva (ibandronate).[32][33]

Risk

The overwhelming majority of BRONJ diagnoses, however, were associated with intravenous administration of bisphosphonates (94%). Only the remaining 6% of cases arose in patients taking bisphosphonates orally.[7]

Although the total United States prescriptions for oral bisphosphonates exceeded 30 million in 2006, less than 10% of BON cases were associated with patients taking oral bisphosphonate drugs.[34] Studies have estimated that BRONJ occurs in roughly 20% of patients taking intravenous zoledronic acid for cancer therapy and in between 0–0.04% of patients taking orally administered bisphosphonates.[35]

Owing to prolonged embedding of bisphosphonate drugs in the bone tissues, the risk for BRONJ is high even after stopping the administration of the medication for several years.[36]

Patients who stopped taking anti-angiogenic drugs are exposed to the same risk as patients who have never taken the drugs because anti-angiogenic drugs are not normally supposed to remain in the body for long period of time.[8]

Risk factors

Risk factors include:[8]

  • Dental treatment (e.g. dentoalveolar surgery/procedure that impacts bone) – it is possible for MRONJ to occur spontaneously without any recent invasive dental treatment
  • Duration of bisphosphonate drug therapy – increased risk with increased cumulative dose of drug
  • Other concurrent medication – use of chronic systemic glucocorticoid increases risk when they are taken in combination with anti-resorptive drugs
  • Dental implants
  • Drug holidays – no evidence to support a reduction in MRONJ risk if patients stop taking bisphosphonates temporarily/permanently, as drugs can persist in skeletal tissues for many years
  • Treatment in the past with anti-resorptive/anti-angiogenic drugs
  • Patient being treated for cancer – higher risk
  • Patients being treated for osteoporosis/non-malignant bone diseases (e.g. Paget's disease) – lower risk

Research findings

MRONJ has become a growing pool of the patient population which has sparked the interest of many dentists and doctors alike. A systematic review and meta-analysis studying the occurrence and risk indicatoris of MRONJ after dental extractions found:

‘The risk of MRONJ after dental extraction was significantly higher in patients treated with ARD (antiresorptive drugs) for oncological reasons (3.2%) than in those treated with ARD for OP (osteoporosis) (0.15%) (p < 0.0001). Dental extraction performed with adjusted extraction protocols decreased significantly MRONJ development. Potential risk indicators such as concomitant medications and pre-existing osteomyelitis were identified.’[37]

Research found that patients on BsPs alone for stage II oncological disease – mainly females- were most frequently diagnosed with MRONJ mainly after dental treatment and bone surgery. ‘ A new population affected by MRONJ is emerging. Men affected by kidney cancer treated with new antiresorptive-antiangiogenic drugs will represent a growing portion of the pool of patients at risk. '

[38]

Patient risk categories

Low:[8]

  • Treatment of osteoporosis or non-malignant bone disease with oral bisphosphonates for <5 years (not taking systemic glucocorticoids)
  • Treatment of osteoporosis or non-malignant bone disease with quarterly/yearly infusions of intravenous bisphosphonates for <5 years (not taking systemic glucocorticoids)
  • Treatment of osteoporosis or non-malignant bone disease with denosumab (not taking systemic glucocorticoids)

High:

  • Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years
  • Patients being treated for osteoporosis or non-malignant bone disease with bisphosphonates/denosumab for any length of time as well as being treated with systemic glucocorticoids
  • Patients being treated with anti-resorptive/anti-angiogenic drugs/both as part of cancer management
  • Previous MRONJ diagnosis

"N.B. Patients who have taken bisphosphonate drugs at any time in the past and those who have taken denosumab in the last nine months are allocated to a risk group as if they are still taking the drug."[8]

Anti-resorptive drugs

Anti-resorptive drugs inhibit osteoclast differentiation and function, slowing down the breakdown of bone.[39] It is usually prescribed for patients with osteoporosis or other metastatic bone diseases, such as Paget's disease, osteogenesis imperfecta and fibrous dysplasia.[40][41]

The two main types of anti-resorptive drugs are bisphosphonate and denosumab. These drugs help to decrease the risk of bone fracture and bone pain.

As mandible has a quicker remodeling rate compare to other bones in the body, it is more affected by the effects of these drugs.[42]

  1. Bisphosphonate
    • Bisphosphonate could be administrated orally or intravenously. It reduces bone resorption.[43]
    • Mechanism of action: Bisphosphonate binds to the mineral component of the bone and inhibits enzymes (i.e. farnesyl-pyrophosphate synthase) that is responsible for bone formation, recruitment and osteoclast function.[41][43]
    • This type of drug has a high affinity to hydroxyapatite[40] and stays in bone tissue for a long period of time,[41] with alendronate, it has a half-life of approximately ten years.[42]
    • The risk of patient having MRONJ after stop taking this medication is unknown.[42]
    • There are suggestions that bisphosphonate may inhibit the proliferation of soft tissue cells and increases apoptosis. This may result in delayed soft tissue healing.[42]
    • Examples of bisphosphonate: : Zoledronic acid (Reclast, Zometa), Risedronate (Actonel), Alendronate (Fosamax), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Tiludronate (Skelid).[44]
  2. Denosumab
    • Denosumab is a monoclonal antibody[45][46] which is administrated subcutaneously. It inhibits osteoclast differentiation and activation, reduces bone resorption, improves bone density and lessens skeletal-related events associated with metastasis.[43]
    • Mechanism of action: The drug binds to receptor activator nuclear factor κB ligand (RANKL), preventing the interaction with RANK.[45][43][46]
    • It does not bind to bone and its effect on bone diminishes in 9 months.[42]

Anti-angiogenic drugs

Osteonecrosis of the jaw has been identified as one of the possible complications after taking anti-angiogenic drugs, the association the disease and medication is known as MRONJ. This have been stated in the Drug Safety Updates by MHRA.[8]

Anti-angiogenic drugs, which is as known as angiogenesis inhibitors obstruct the blood vessels formation by interfering the angiogenesis signalling cascade. They are used primarily to treat cancer. It is different from other conventional cancer drugs as these cancer-fighting agents tend to hinder the growth of blood vessels that supply the tumour rather than killing tumour cells directly.[47] It does not necessary eliminate tumours but it has indirect on treating cancer by preventing the tumour from growing. For example, bevacizumab/ aflibercept is a monoclonal antibody that specifically bind to the vascular endothelial growth factor (VEGF), so the VEGF is no longer available to bind to the receptors on the surface of normal endothelial cells.[48] Sunitinib is a different example of anti-angiogenic drugs as it inhibits cellular signalling by targeting multiple receptor tyrosine kinases. It reduces blood/ nutrients supply to tumour by inhibiting new blood vessels formation from the cancer cells.[49] Hence, the tumour stops growing or even shrinks.[50]

Prevention

Dentoalveolar surgery is a risk factor for development of BRONJ. Prevention including the maintenance of good oral hygiene, comprehensive dental examination and dental treatment including extraction of teeth of poor prognosis and dentoalveolar surgery should completed prior to commencing any medication which is likely to cause osteonecrosis (ONJ). Patients with removable prostheses should be examined for areas of mucosal irritation. Procedures which are likely to cause direct osseous trauma, e.g. tooth extraction, dental implants, complex restoration, deep root planning, should be avoided in preference of other dental treatments. Some[who?] have advocated "drug holidays", but this remains controversial.[citation needed]

Management

Bisphosphonate-related osteonecrosis of the jaw (BRONJ), now referred to as Medication-related osteonecrosis of the jaw (MRONJ) is an adverse reaction which can occur as a result of medicines used to treat cancer and osteoporosis.[51] Some medications which induce these effects are Bisphosphonates, Denosumab and Antiangiogenic agents. They involve the destruction of bone in a progressive manner, particularly associated with the mandible or maxilla. The overall effects depend on which drug is being used, the dose and the duration of taking this drug. MRONJ is associated with significant severe disease, negative affects on the quality of life and remains to be increasingly challenging to treat.[52] It is of high debate whether the various management techniques used for MRONJ are effective or not but due to the severity of the disease it is continually understood action must be taken.[53] The management of patients taking the drugs of concern undergo initial management and continuing management. Before either of these are considered the patient must be as dentally fit as possible.

Initial management

This involves patients who are about to start, or very recently have started, taking the drugs of concern. There is a small portion of observational studies which promote the idea of preventative dental treatment to decrease oral complications in patients taking these drugs. These preventative measures may require a change in the patients’ oral hygiene technique and lifestyle factors such as smoking and alcohol consumption. There is also a benefit in prescribing high fluoridated toothpaste if the patient is of high caries risk. Before prescribing of any kind or when noticing a patient is on the treatment already, it is encouraged to tell the patient of the risk of developing MRONJ, although this risk is small. This is followed by personalised advice given to the patient, involving: a healthy diet, excellent oral hygiene, stop smoking, limited alcohol consumption and regular dental appointments. If a patient has a complex medical history and is of particular high risk it is advised before any treatment to commence, communication with a specialist with regards to the clinical assessment and treatment plan. It is also advised for individuals who take bisphosphonates to never allow the tablet to dissolve in the mouth as this causes damage to the oral mucosa. The patient must follow the instructions given with the tablets.

Continuing management

This involves patients who have a regime which actively incorporates the drugs of concern and also for the patients whom undergone initial management. In terms of dental treatment all must be done as normal, accompanied by personalised advice to the patient. If there is a need for an extraction or any procedure which implicates bone a discussion with the patient about the risks and benefits must occur. Due to bacterial resistance and possible side effects of antibiotic therapy, they are only prescribed if there is a necessity for them. There is minimal evidence to say the use of prophylactic antibiotics will reduce MRONJ.[8]

For some patients, it is possible to have a drug holiday during which bisphosphonates are discontinued if the benefit of discontinuing the drug outweighs the risks. If it is possible to have a drug holiday, it is recommended that treatment be carried out during that period. Some patients however have been taking the drug for a prolonged period of time and so the bisphosphonate levels have accumulated in the body. In this case, a drug holiday would be of no benefit.[54]

Medical management of MRONJ is most commonly performed for patients who have less severe cases or those whom have contraindicating health conditions. The antimicrobials therapies commonly used are topical, oral and intravenous.

Topical antimicrobials

A commonly used medicament, chlorhexidine gluconate 0.12% is bacteriostatic and bacteriocidal making an effective agent against MRONJ. Advantages of this topical gel is the low cost, ease of use, availability and patient acceptance. The disadvantages of this are the low compliance, patient acceptance, dental staining and risk of opportunistic bacterial resistance. For some patients, it is possible to have a drug holiday during which bisphosphonates are discontinued if the benefit of discontinuing the drug outweighs the risks. If it is possible to have a drug holiday, it is recommended that treatment be carried out during that period. Some patients however have been taking the drug for a prolonged period of time and so the bisphosphonate levels have accumulated in the body. In this case, a drug holiday would be of no benefit.For some patients, it is possible to have a drug holiday during which bisphosphonates are discontinued if the benefit of discontinuing the drug outweighs the risks. If it is possible to have a drug holiday, it is recommended that treatment be carried out during that period. Some patients however have been taking the drug for a prolonged period of time and so the bisphosphonate levels have accumulated in the body. In this case, a drug holiday would be of no benefit.

Oral antimicrobials

The use of these are based on the clinical evaluation of the condition and if pathogenic bacteria presence is indicated. This is generally a 2-week course for a patient with a persistent presentation of the disease or a 4-6 week course for more severe cases. Penicillin is the first line of choice, although if this is contraindicated commonly used antimicrobials are: clindamycin, fluoroquinolones and/or metronidazole.

Intravenous antimicrobials

This means of therapy may be of benefit with patients who possess specific pathogenic organisms which resist oral therapies. Although this method has perceived greater penetration of tissue there is little evidence of being a substantial greater efficacy when compared to other methods of management.[55]

Advanced methods of management

Although there are many methods of managing MRONJ there is no definitive treatment as of yet. Recently there has been regenerative concepts using stem cells from a variety of sources combined with growth factors, in order to treat MRONJ. This gives a promising future for management but is not yet a routine procedure.[56]

Treatment

Treatment usually involves antimicrobial mouth washes and oral antibiotics to help the immune system fight the attendant infection, and it also often involves local resection of the necrotic bone lesion. Many patients with MRONJ have successful outcomes after treatment, meaning that the local osteonecrosis is stopped, the infection is cleared, and the mucosa heals and once again covers the bone.

The treatment the person receives depends on the severity of osteonecrosis of the jaw.

Conservative

Indicated in patients who have evidence of exposed bone but no evidence of infection. It may not necessarily eliminate all the lesions, but it may provide patients with a long term relief. This approach involves a combination of antiseptic mouthwashes and analgesics and the use of teriparatide.[57] However, note that the teriparatide treatment should not be used in cancer patients, or patients with a history of skeletal radiation or active bone metastases. Splints may be used to protect sites of exposed necrotic bone.

Non-surgical

Indicated for patients with exposed bone with symptoms of infection. This treatment modality may also be utilised for patients with other co-morbidities which precludes invasive surgical methods. This approach requires antimicrobial mouthwashes, systemic antibiotics and antifungal medication and analgesics.[58]

Surgery

Surgical intervention is indicated in patients with symptomatic exposed bone with fistula formation and one or more of the following: exposed and necrotic bone extending beyond the alveolar bone resulting in pathological fracture; extra-oral fistula; oral antral communication or osteolysis extending from the inferior border of the mandible or the sinus floor. Surgical management involves necrotic bone resection, removal of loose sequestra of necrotic bone and reconstructive surgery. The objective of surgical management is to eliminate areas of exposed bone to prevent the risk of further inflammation and infection. The amount of surgical debridement required remains controversial.

Other

Surgical management – bone fluorescence

Reducing number of cases of MRONJ in people receiving intravenous bisphosphonates was achieved by administrating antibiotics before extractions, using techniques of closing bone so that the underlying bone was not exposed. These are called preventative measures. Other ways of reducing the number of MRONJ cases was having dental exams every 3 months.

There is some evidence for and against hyperbaric oxygen therapy as something that will treat MRONJ.

Another thing that may be helpful to treat MRONJ, but does not necessarily have a lot of data to back it up is fluorescence- guided bone surgery. There is a debate whether auto fluorescence guided or tetracycline fluorescence guided bone surgery is better.

A difficulty in managing MRONJ is that vital and necrotic bone are very difficult to tell the difference between. Bone fluorescence which is caused by tetracycline and auto fluorescence is a very good method of being able to see necrotic bone. Researchers have found out that using this antibiotic helps because it has a high penetration level of the bone, this will cause increased fluorescence.[61] The necrotic bone is not fluorescent and the viable bone is fluorescent. The necrotic bone also may show an altered pattern of fluorescence.

A study[62] was done comparing 20 people having auto fluorescence guided bone surgery and 20 people having tetracycline fluorescence guided bone surgery.

The point being looked at in the study is treatment success, meaning that 8 weeks after surgery there was no exposed bone.

Other things measured were: mucosal integrity, infection, pain, loss of sensitivity.

These were analyzed at 10 days, 8 weeks, 6 months and a year after surgery.

The results are as follows:[62] there was better mucosal integrity and mucosal coverage with no exposed bone in patients who had had the auto fluorescence guided bone surgery but no difference in all other aspects. In conclusion, both methods are comparable.

Regardless which way is used during bone surgery; the advantages of florescence techniques are that minimal bone can be taken away. Only the necessary bone will be taken away which leaves more viable bone.

Fluorescence can also be used to detect surface mucosa that isn't normal. Fluorescence is used in the gut, the lungs, and in the mouth. It is a very useful tool. Clinical uses can be radiating the mucosa needing to be examined with a special blue light, and observing the light that is emitted through a visor. Fluorescence is shown with perfectly normal tissues but with tissues that have pathological problems, the areas are shown as 'dark stains'.[61]

See also

References

  1. ^ Nase JB, Suzuki JB (August 2006). "Osteonecrosis of the jaw and oral bisphosphonate treatment". J Am Dent Assoc. 137 (8): 1115–9, quiz 1169–70. doi:10.14219/jada.archive.2006.0350. PMID 16873327.
  2. ^ Marx, RE (2003). "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic". Journal of Oral and Maxillofacial Surgery. 61 (9): 1115–7. doi:10.1016/s0278-2391(03)00720-1. PMID 12966493.
  3. ^ Migliorati, CA (2003). "Bisphosphonates and oral cavity avascular bone necrosis". Journal of Clinical Oncology. 21 (22): 4253–4. doi:10.1200/JCO.2003.99.132. PMID 14615459.
  4. ^ a b Ruggiero, SL (2007). "Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ)". Clinical Cases in Mineral and Bone Metabolism. 4 (1): 37–42. doi:10.1016/j.joms.2014.04.031. PMID 25234529.
  5. ^ Sigua-Rodriguez, EA (2014). "Bisphosphonate-related osteonecrosis of the jaw: a review of the literature". International Journal of Dentistry. 2014: 1–5. doi:10.1155/2014/192320. PMC 4020455. PMID 24868206.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  6. ^ Abu-Id, Mario; et al. (2008). "'Bis-phossy jaws' – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw". Journal of Cranio-Maxillofacial Surgery. 36 (2): 95–103. doi:10.1016/j.jcms.2007.06.008. PMID 18234504. {{cite journal}}: Explicit use of et al. in: |last2= (help)
  7. ^ a b c Osteoporosis medications and your dental health pamphlet #W418, American Dental Association/National Osteoporosis Foundation, 2008
  8. ^ a b c d e f g h i "Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw" (PDF). Scottish Dental Clinical Effectiveness Programme. March 2017.
  9. ^ Dodson, TB (2015). "The frequency of medication-related ssteonecrosis of the jaw and its associated risk factors". Oral and Maxillofacial Surgery Clinics of North America. 27 (4): 509–16. doi:10.1016/j.coms.2015.06.003. PMID 26362367.
  10. ^ Ruggiero SL, Dodson TB, Fantasia J; et al. (2014). "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update". Journal of Oral and Maxillofacial Surgery. 72 (10): 1938–1956. doi:10.1016/j.joms.2014.04.031. PMID 25234529. {{cite journal}}: Explicit use of et al. in: |last= (help)CS1 maint: multiple names: authors list (link)
  11. ^ Marx RE (September 2003). "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic". J. Oral Maxillofac. Surg. 61 (9): 1115–7. doi:10.1016/S0278-2391(03)00720-1. PMID 12966493.
  12. ^ Migliorati CA (November 2003). "Bisphosphanates and oral cavity avascular bone necrosis". J. Clin. Oncol. 21 (22): 4253–4. doi:10.1200/JCO.2003.99.132. PMID 14615459.
  13. ^ Appendix 11: Expert Panel Recommendation for the Prevention, Diagnosis and Treatment of Osteonecrosis of the Jaw
  14. ^ Lehrer S, Montazem A, Ramanathan L, et al. (January 2009). "Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene". J. Oral Maxillofac. Surg. 67 (1): 159–61. doi:10.1016/j.joms.2008.09.015. PMID 19070762.
  15. ^ a b Ruggiero SL (March 2008). "Bisphosphonate-related Osteonecrosis of the Jaws". Compendium of Continuing Education in Dentistry. 29 (2): 97–105.
  16. ^ Allen, Matthew R.; Ruggiero, Salvatore L. (2009-07-01). "Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw". Journal of Oral and Maxillofacial Surgery. 67 (7): 1373–1377. doi:10.1016/j.joms.2009.03.048. ISSN 1531-5053. PMID 19531405.
  17. ^ a b Khan, Aliya A.; Morrison, Archie; Hanley, David A.; Felsenberg, Dieter; McCauley, Laurie K.; O'Ryan, Felice; Reid, Ian R.; Ruggiero, Salvatore L.; Taguchi, Akira (2015-01-01). "Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus". Journal of Bone and Mineral Research. 30 (1): 3–23. doi:10.1002/jbmr.2405. ISSN 1523-4681. PMID 25414052.
  18. ^ Zadik Y, Benoliel R, Fleissig Y, Casap N (February 2012). "Painful trigeminal neuropathy induced by oral bisphosphonate-related osteonecrosis of the jaw: a new etiology for the numb-chin syndrome". Quintessence Int. 43 (2): 97–104. PMID 22257870.
  19. ^ a b c d e f Sharma, Dileep; Ivanovski, Saso; Slevin, Mark; Hamlet, Stephen; Pop, Tudor S.; Brinzaniuc, Klara; Petcu, Eugen B.; Miroiu, Rodica I. (2013-01-01). "Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect". Vascular Cell. 5 (1): 1. doi:10.1186/2045-824X-5-1. ISSN 2045-824X. PMC 3606312. PMID 23316704.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  20. ^ Goodell, Dr. Gary G. (Fall 2012). "Endodontics: Colleagues for Excellence" (PDF). American Association of Endodontists. 211 E. Chicago Ave., Suite 1100 Chicago, IL 60611-2691: American Association of Endodontists.{{cite web}}: CS1 maint: location (link) CS1 maint: year (link)
  21. ^ Otto, Sven; Hafner, Sigurd; Grötz, Knut A. (2009-03-01). "The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw". Journal of Oral and Maxillofacial Surgery. 67 (3): 589–592. doi:10.1016/j.joms.2008.09.028. ISSN 1531-5053. PMID 19231785.
  22. ^ Baron, Roland; Ferrari, Serge; Russell, R. Graham G. (2011-04-01). "Denosumab and bisphosphonates: different mechanisms of action and effects". Bone. 48 (4): 677–692. doi:10.1016/j.bone.2010.11.020. ISSN 1873-2763. PMID 21145999.
  23. ^ Russell, R. G. G.; Watts, N. B.; Ebetino, F. H.; Rogers, M. J. (2008-06-01). "Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy". Osteoporosis International: A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 19 (6): 733–759. doi:10.1007/s00198-007-0540-8. ISSN 0937-941X. PMID 18214569.
  24. ^ Lindsay R, Cosman F. Osteoporosis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison’s principles of internal medicine. New York:McGraw-Hill, 2001:2226-37.
  25. ^ Wood, J; Bonjean, K; Ruetz, S; Bellahcene, A; Devy, L; Foidart, JM; Castronovo, V; Green, JR (2002). "Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid". J Pharmacol Exp Ther. 302 (3): 1055–61. doi:10.1124/jpet.102.035295. PMID 12183663.
  26. ^ Vincenzi, B; Santini, D; Dicuonzo, G; Battistoni, F; Gavasci, M; La Cesa, A; Grilli, C; Virzi, V; Gasparro, S; Rocci, L; Tonini, G (2005). "Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients". J Interferon Cytokine Res. 25 (3): 144–51. doi:10.1089/jir.2005.25.144. PMID 15767788.
  27. ^ Santini, D; Vincenzi, B; Dicuonzo, G; Avvisati, G; Massacesi, C; Battistoni, F; Gavasci, M; Rocci, L; Tirindelli, MC; Altomare, V; Tocchini, M; Bonsignori, M; Tonini, G (2003). "Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients". Clin Cancer Res. 9 (8): 2893–7. PMID 12912933.
  28. ^ Chapurlat, Roland D; Arlot, Monique; Burt-Pichat, Brigitte; Chavassieux, Pascale; Roux, Jean Paul; Portero-Muzy, Nathalie; Delmas, Pierre D (2007-10-01). "Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study". Journal of Bone and Mineral Research. 22 (10): 1502–1509. doi:10.1359/jbmr.070609. ISSN 1523-4681. PMID 17824840.
  29. ^ Stepan, Jan J.; Burr, David B.; Pavo, Imre; Sipos, Adrien; Michalska, Dana; Li, Jiliang; Fahrleitner-Pammer, Astrid; Petto, Helmut; Westmore, Michael (2007-09-01). "Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis". Bone. 41 (3): 378–385. doi:10.1016/j.bone.2007.04.198. ISSN 8756-3282. PMID 17597017.
  30. ^ Woo, Sook-Bin; Hellstein, John W.; Kalmar, John R. (2006-05-16). "Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws". Annals of Internal Medicine. 144 (10): 753–761. CiteSeerX 10.1.1.501.6469. doi:10.7326/0003-4819-144-10-200605160-00009. ISSN 1539-3704. PMID 16702591.
  31. ^ Medical News Today AAOMS Updates BRONJ Position Paper, January 23, 2009
  32. ^ American Dental Association Osteonecrosis of the Jaw
  33. ^ "Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis" (PDF). nos.org.uk. The National Osteoporosis Society. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  34. ^ Grbic JT, Landesberg R, Lin SQ, et al. (January 2008). "Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial". J Am Dent Assoc. 139 (1): 32–40. doi:10.14219/jada.archive.2008.0017. PMID 18167382.
  35. ^ Cartsos VM, Zhu S, Zavras AI (January 2008). "Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people". J Am Dent Assoc. 139 (1): 23–30. doi:10.14219/jada.archive.2008.0016. PMID 18167381.[permanent dead link]
  36. ^ Zadik Y, Abu-Tair J, Yarom N, Zaharia B, Elad S (September 2012). "The importance of a thorough medical and pharmacological history before dental implant placement". Aust Dent J. 57 (3): 388–392. doi:10.1111/j.1834-7819.2012.01717.x. PMID 22924366.
  37. ^ Gaudin, Seidel, Bacevic, Rompen, Lambert, Elise, Laurence , Miljana , Eric, Lambert (October 2015). "Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis". {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)
  38. ^ G.Ghidini, M.Manfredi, I.Giovannacci, G.Mergoni, A.Sarraj, M.Mureddu, G.Giunta, M.Bonanini , M.Meleti, P. Vescovi (August 2017). "Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs". {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)
  39. ^ "Anti-resorptive Medical Definition". Retrieved 19 February 2018.
  40. ^ a b Drake, Matthew T.; Clarke, Bart L.; Khosla, Sundeep (September 2008). "Bisphosphonates: Mechanism of Action and Role in Clinical Practice". Mayo Clinic Proceedings. 83 (9): 1032–1045. doi:10.4065/83.9.1032. ISSN 0025-6196. PMC 2667901. PMID 18775204.
  41. ^ a b c Martin, T John (2000-06-01). "Experimental and Clinical Pharmacology: Bisphosphonates - mechanisms of action". Australian Prescriber. 23 (6): 130–132. doi:10.18773/austprescr.2000.144.
  42. ^ a b c d e Michaelina Macluskey, Stephanie Sammut (March 2017). Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw Dental Clinical Guidance. SDCEP. pp. 4, 5.{{cite book}}: CS1 maint: year (link)
  43. ^ a b c d Baron, Roland; Ferrari, Serge; Russell, R. Graham G. (2011). "Denosumab and bisphosphonates: Different mechanisms of action and effects". Bone. 48 (4): 677–692. doi:10.1016/j.bone.2010.11.020. PMID 21145999.
  44. ^ Samuel Durham, Rebecca Miller, Caryn Davis, Brian M (May 20, 2010). "Bisphosphonate Nephrotoxicity Risks and Use in CKD Patients". U.S. Pharmacist.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  45. ^ a b Dahiya, Navdeep; Khadka, Anjan; Sharma, A.K.; Gupta, A.K.; Singh, Nishith; Brashier, D.B.S. (January 2015). "Denosumab: A bone antiresorptive drug". Medical Journal, Armed Forces India. 71 (1): 71–75. doi:10.1016/j.mjafi.2014.02.001. ISSN 0377-1237. PMC 4297848. PMID 25609868.
  46. ^ a b McClung, Michael R. (2017). "Denosumab for the treatment of osteoporosis". Osteoporosis and Sarcopenia. 3 (1): 8–17. doi:10.1016/j.afos.2017.01.002.
  47. ^ "Angiogenesis Inhibitors". National Cancer Institute. May 2018. Retrieved 2018-02-19.
  48. ^ Rosella, Daniele; Papi, Piero; Giardino, Rita; Cicalini, Emauele; Piccoli, Luca; Pompa, Giorgio (2016). "Medication-related osteonecrosis of the jaw: Clinical and practical guidelines". Journal of International Society of Preventive & Community Dentistry. 6 (2): 97–104. doi:10.4103/2231-0762.178742. ISSN 2231-0762. PMC 4820581. PMID 27114946.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  49. ^ Al-Husein, Belal; Abdalla, Maha; Trepte, Morgan; Deremer, David L.; Somanath, Payaningal R. (December 2012). "Antiangiogenic therapy for cancer: an update". Pharmacotherapy. 32 (12): 1095–1111. doi:10.1002/phar.1147. ISSN 1875-9114. PMC 3555403. PMID 23208836.
  50. ^ Hao, Zhonglin; Sadek, Ibrahim (2016-09-08). "Sunitinib: the antiangiogenic effects and beyond". OncoTargets and Therapy. 9: 5495–5505. doi:10.2147/OTT.S112242. ISSN 1178-6930. PMC 5021055. PMID 27660467.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  51. ^ Beth-Tasdogan, N. H., Mayer, B., Hussein, H., & Zolk, O. (2017). "Interventions for managing medication-related osteonecrosis of the jaw". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  52. ^ Institute of Pharmacology of Natural Products & Clinical Pharmacology, Ulm University, Helmholtzstr. 20, Ulm, Germany, 89081.
  53. ^ Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. J Am Dent Assoc. 2017 Aug
  54. ^ Lam, David K.; Sándor, George K. B.; Holmes, Howard I.; Evans, A. Wayne; Clokie, Cameron M. L. (June 2007). "A review of bisphosphonate-associated osteonecrosis of the jaws and its management". Journal of the Canadian Dental Association. 73 (5): 417–422. ISSN 1488-2159. PMID 17555652.
  55. ^ Management of Medication-related Osteonecrosis of the Jaw, An Issue of Oral and Maxillofacial Clinics of North America 27-4. 7 Jan 2016. Salvatore L. Ruggiero
  56. ^ Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents 27 Nov 2014. Sven Otto
  57. ^ Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O’Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K. Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston (April 2014). "Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus". JBMR. 30 (1): 3–23. doi:10.1002/jbmr.2405. PMID 25414052. {{cite journal}}: Unknown parameter |last-author-amp= ignored (|name-list-style= suggested) (help)
  58. ^ Svejda, B.; Muschitz, Ch; Gruber, R.; Brandtner, Ch; Svejda, Ch; Gasser, R. W.; Santler, G.; Dimai, H. P. (1946). "[Position paper on medication-related osteonecrosis of the jaw (MRONJ)]". Wiener Medizinische Wochenschrift. 166 (1–2): 68–74. doi:10.1007/s10354-016-0437-2. ISSN 1563-258X. PMID 26847441.
  59. ^ R. Fliefel; M. Tro¨ltzsch; J. Kühnisch; M. Ehrenfeld; S. Otto (May 2015). "Treatment strategies and outcomes of bisphosphonaterelated osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review". International Journal of Oral and Maxillofacial Surgery. 44 (5): 568–85. doi:10.1016/j.ijom.2015.01.026. PMID 25726090.
  60. ^ Blus, Cornelio (23 August 2013). "Use of Ultrasonic Bone Surgery (Piezosurgery) to Surgically Treat Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ). A Case Series Report with at Least 1 Year of Follow-Up". The Open Dentistry Journal. 7 (1): 94–101. doi:10.2174/1874210601307010094. PMC 3772575. PMID 24044030.
  61. ^ a b Auto fluorescence image of post-radiation maxillary bone osteonecrosis in a 64-year-old patient – Case Report Aleksandra Szczepkowska1, Paweł Milner1, Anna Janas 1 Institute of Dental Surgery, Medical University, Łódź, Poland
  62. ^ a b Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. Ristow O1, Otto S2, Geiß C3, Kehl V4, Berger M5, Troeltzsch M2, Koerdt S6, Hohlweg-Majert B7, Freudlsperger C5, Pautke C3.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Medication-related_osteonecrosis_of_the_jaw&oldid=862700883"